Tolerability of ADXS11-001 Lm-LLO Listeria-Based Immunotherapy With Mitomycin, Fluorouracil, and Radiation for Anal Cancer

Howard Safran, Kara Lynne Leonard, Kimberly Perez, Matthew Vrees, Adam Klipfel, Steven Schechter, Nicklas Oldenburg, Leslie Roth, Nishit Shah, Kayla Rosati, Lakshmi Rajdev, Kalyan Mantripragada, Iris Y. Sheng, Peter Barth, Thomas A. DiPetrillo

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Purpose: To obtain safety and preliminary efficacy data of the combination of ADXS11-001, live attenuated Listeria monocytogenes bacterium, with mitomycin, 5-fluorouracil (5-FU), and intensity modulated radiation therapy in locally advanced anal cancer. Patients and Methods: Eligibility included patients with previously untreated, nonmetastatic anal cancer with a primary tumor >4 cm or node-positive disease. Patients received 2 cycles of mitomycin and 5-FU concurrent with 54.0 Gy intensity modulated radiation therapy. One intravenous dose of ADXS11-001 (1 × 109 colony-forming units) was administered before chemoradiation; 3 additional monthly doses were given after chemoradiation. Results: Ten patients were treated, including 1 with N2 and 4 with N3 disease. Two patients had grade 3 acute toxicities after the initial dose of ADXS11-001, including chills/rigors (n = 2), back pain (n = 1), and hyponatremia (n = 1). All ADXS11-001 toxicities occurred within 24 hours of administration. There was no apparent increase in chemoradiation toxicities or myelosuppression. One patient had a grade 5 cardiopulmonary event shortly after beginning 5-FU treatment. All 9 assessable patients had complete clinical responses by sigmoidoscopy. Eight of 9 patients (89%) are progression-free at a median follow-up of 42 months. Conclusions: Preliminary data show that ADXS11-001 can be safely administered with standard chemoradiation for anal cancer. Further studies of listeria-based immunotherapy with radiation are warranted.

Original languageEnglish (US)
Pages (from-to)1175-1178
Number of pages4
JournalInternational Journal of Radiation Oncology Biology Physics
Volume100
Issue number5
DOIs
StatePublished - Apr 1 2018

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'Tolerability of ADXS11-001 Lm-LLO Listeria-Based Immunotherapy With Mitomycin, Fluorouracil, and Radiation for Anal Cancer'. Together they form a unique fingerprint.

  • Cite this

    Safran, H., Leonard, K. L., Perez, K., Vrees, M., Klipfel, A., Schechter, S., Oldenburg, N., Roth, L., Shah, N., Rosati, K., Rajdev, L., Mantripragada, K., Sheng, I. Y., Barth, P., & DiPetrillo, T. A. (2018). Tolerability of ADXS11-001 Lm-LLO Listeria-Based Immunotherapy With Mitomycin, Fluorouracil, and Radiation for Anal Cancer. International Journal of Radiation Oncology Biology Physics, 100(5), 1175-1178. https://doi.org/10.1016/j.ijrobp.2018.01.004